Cell Growth & Differentiation, Vol 3, Issue 10 723-730, Copyright © 1992 by American Association of Cancer Research

ARTICLES

Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa

RG Ramsay, MA Thompson, JA Hayman, G Reid, TJ Gonda and RH Whitehead
Melbourne Tumour Biology Branch, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Australia.

Expression of the protooncogene c-Myb protein was assessed in normal mucosa and in tumor samples resected from six patients. We found that the tumor samples always expressed higher levels of full length Myb protein than the normal tissue. This contrasts with the situation in c-myb-associated hemopoietic malignancies of the mouse and chicken, in which Myb proteins are generally amino or carboxyl truncated. Tissues from five patients with colonic adenomatous polyps were also examined and found to express levels of Myb that were, in general, intermediate between those found in normal tissues and tumors. Of particular interest is that the more dysplastic polyps displayed higher Myb levels. In one patient with carcinoma and multiple colonic polyps, some polyps had intermediate levels of Myb, whereas one polyp with carcinoma in situ expressed tumor-like levels of Myb. To directly test the hypothesis that Myb expression may be important in determining the rate of colonic cell proliferation, we examined three colonic carcinoma cell lines and one polyp cell line. We found that the cell lines with the most rapid doubling times exhibited the highest Myb levels. In addition, we show that antisense myb oligonucleotides retard the proliferation of one of these colonic cell lines which expresses the highest level of Myb.

This article has been cited by other articles:

				S. L. Palumbo, R. M. Memmott, D. J. Uribe, Y. Krotova-Khan, L. H. Hurley, and S. W. Ebbinghaus A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity Nucleic Acids Res., April 1, 2008; 36(6): 1755 - 1769. [Abstract] [Full Text] [PDF]

				R. G. Ramsay, S. Micallef, S. Lightowler, M. L. Mucenski, T. Mantamadiotis, and I. Bertoncello c-myb Heterozygous Mice Are Hypersensitive to 5-Fluorouracil and Ionizing Radiation Mol. Cancer Res., June 1, 2004; 2(6): 354 - 361. [Abstract] [Full Text] [PDF]

				G. Davies, L.-A. Martin, N. Sacks, and M. Dowsett Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention Ann. Onc., May 1, 2002; 13(5): 669 - 678. [Abstract] [Full Text] [PDF]

				A. Biroccio, B. Benassi, I. D'Agnano, C. D'Angelo, S. Buglioni, M. Mottolese, A. Ricciotti, G. Citro, M. Cosimelli, R. G. Ramsay, et al. c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer : Clinical and Experimental Findings Am. J. Pathol., April 1, 2001; 158(4): 1289 - 1299. [Abstract] [Full Text] [PDF]

				R. G. Ramsay, A. Friend, Y. Vizantios, R. Freeman, C. Sicurella, F. Hammett, J. Armes, and D. Venter Cyclooxygenase-2, a Colorectal Cancer Nonsteroidal Anti-inflammatory Drug Target, Is Regulated by c-MYB Cancer Res., April 1, 2000; 60(7): 1805 - 1809. [Abstract] [Full Text]